Minocycline in neurodegenerative and psychiatric diseases: An update
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Background and purpose: Minocycline is a broad‐spectrum antibiotic, effective as a chronic treatment for recurrent bacterial infections. Beyond its antibiotic action, minocycline also has important anti‐inflammatory, antioxidant and antiapoptotic properties. Its efficacy has therefore been evaluated in many neurodegenerative and psychiatric diseases that have an inflammatory basis. Our aim was to review preclinical and clinical studies performed in neurological and psychiatric diseases whose treatment involved the use of minocycline and thereby to discern the possible beneficial effect of minocycline in these disorders. Methods: Completed and ongoing preclinical studies and clinical trials of minocycline for both neurodegenerative diseases and psychiatric disorders, published from January 1995 to January 2020, were identified through searching relevant databases (https://www.ncbi.nlm.nih.gov/pubmed/, https://clinicaltrials.gov/). A total of 74 preclinical studies and 44 clinical trials and open‐label studies were selected. Results: The results of the nearly 20 years of research identified are diverse. While minocycline mostly proved to be effective in animal models, clinical results showed divergent outcomes, with positive results in some studies counterbalanced by a number of cases with no significant improvements. Specific data for each disease are further individually described in this review. Conclusions: Despite minocycline demonstrating antioxidant and anti‐inflammatory effects, discrepancies between preclinical and clinical data indicate that we should be cautious in analyzing the outcomes. Improving and standardizing protocols and refining animal models could help us to determine if minocycline really is a useful drug in the treatment of these pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lord, C., Elsabbagh, M., Baird, G., & Veenstra-Vanderweele, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31129-2 · Cited by 2,819
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
O'Connor, J. C., Lawson, M. A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002148 · Cited by 1,278 · cited 1×
“Since the first preclinical study in 2007, several studies have shown that minocycline improves anxiety in different behavioral tests, especially forced swimming, tail suspension and open field tests [131-139], together with reduction of inflammation and/or inflammatory mediators [132,135,137,139-142] and recovery of…”
BackgroundWu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 5×
“By contrast, two studies on the MPTP model showed deleterious effects caused by minocycline administration, together with increased MPTP toxicity in dopaminergic neurons [43,44].”
BackgroundInfluentialAutophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039 · cited 1×
“In addition, apoptosis plays an important role in the etiology of HD [49], with minocycline being proposed as a candidate for alleviating or delaying the onset of this disease given its neurogenic potential.”
BackgroundMinocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Toward a neurobiology of obsessive-compulsive disorder
Graybiel, A. M., & Rauch, S. L. (2000) · Neuron · doi:10.1016/s0896-6273(00)00113-6 · Cited by 864 · cited 1×
“It involves the dysfunction of glutamatergic neurotransmission in the basal ganglia and orbitofrontal cortex, together with an increase in oxidative stress, among other causes [153,154].”
BackgroundEfficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70270-3 · Cited by 649
Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465 · cited 1×
“The remaining studies, performed in the Fmr1-KO mice model, reported behavioral improvements in locomotor activity, anxiety and exploratory memory [120-123], increment of dendritic spines maturation [120], reduction of seizure severity in young mice [122], and recovery in the function of the N-methyl-D-aspartate (NMDA…”
BackgroundThe NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Wang, Y.-L., Han, Q.-Q., Gong, W.-Q., Pan, D.-H., Wang, L.-Z., Hu, W., Yang, M., Li, B., Yu, J., & Liu, Q. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1054-3 · Cited by 438
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387 · cited 1×
“One RCT reported a reduction of negative symptoms and an improvement of some executive functions after 6 months of minocycline treatment in early-phase SCZ patients as adjuvant to their usual antipsychotic medication (200 mg/day) [105].”
BackgroundLeigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., et al. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318287cd17 · Cited by 298
Inhibition of autoimmune encephalomyelitis by a tetracycline
Popovic, N., Schubart, A., Goetz, B. D., Zhang, S., Linington, C., & Duncan, I. D. (2002) · Annals of Neurology · doi:10.1002/ana.10092 · Cited by 295 · cited 1×
“The first studies reported a decreased T-cell migration, together with MMP inhibition [82], and reduced severity of the symptoms [83,84].”
BackgroundSriram, K., Miller, D. B., & O'Callaghan, J. P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03566.x · Cited by 242 · cited 5×
“By contrast, two studies on the MPTP model showed deleterious effects caused by minocycline administration, together with increased MPTP toxicity in dopaminergic neurons [43,44].”
BackgroundInfluentialOpen-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · cited 1×
“Furthermore, an OLS and an RCT of minocycline-treated children with FXS reported an improvement in irritability and clinical global impression after 8 weeks [126-128], together with reduction of plasmatic MMP-9 [127,128].”
Inflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222 · cited 1×
“Among other factors, the increment of pro-inflammatory cytokines and inflammation [26], mainly generated by an increase in reactive microglia, seem to be the main features involved in PD etiopathogenesis [27].”
BackgroundMiyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., Araki, T., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.002 · Cited by 212
Tomás-Camardiel, M., Rite, I., Herrera, A. J., de Pablos, R. M., Cano, J., Machado, A., & Venero, J. L. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.010 · Cited by 203 · cited 1×
“In different rodent models, minocycline proved to be effective as a neuroprotective agent against diverse compounds with parkinsonian-like effects, such as the neurotoxins 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [28-31], 6-hydroxydopamine (6-OHDA) [32], rotenone [33-35] or paraquat [31], and other compound…”
BackgroundHoward, R., Zubko, O., Bradley, R., Harper, E., Pank, L., O’Brien, J., Fox, C., Tabet, N., Livingston, G., Bentham, P., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3762 · Cited by 194
Deleterious Effects of Minocycline in Animal Models of Parkinson’s Disease and Huntington’s Disease
Diguet, E., Fernagut, P., Wei, X., Du, Y., Rouland, R., Gross, C., Bezard, E., & Tison, F. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03372.x · Cited by 189
Biscaro, B., Lindvall, O., Tesco, G., Ekdahl, C. T., & Nitsch, R. M. (2012) · Neurodegenerative Diseases · doi:10.1159/000330363 · Cited by 164 · cited 1×
“Furthermore, a behavioral improvement, in terms of learning and memory, was also addressed [15,19,22,23].”
BackgroundHigh MMP-9 activity levels in fragile X syndrome are lowered by minocycline
Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., Durbin‐Johnson, B., Hagerman, R. J., & Tassone, F. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36023 · Cited by 161 · cited 4×
“At a molecular level, a reduction in MMP-9 and an increase in vascular cell adhesion molecule (vCAM) and interleukin (IL)-12p40 in serum were shown, which was accompanied by a reduction of the brain lesions and a lower relapse risk [91- 93].”
InfluentialMinocycline Enhances MPTP Toxicity to Dopaminergic Neurons
Yang, L., Sugama, S., Chirichigno, J. W., Gregorio, J., Lorenzl, S., Shin, D. H., Browne, S. E., Shimizu, Y., Joh, T. H., Beal, M. F., et al. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10709 · Cited by 158 · cited 1×
“By contrast, two studies on the MPTP model showed deleterious effects caused by minocycline administration, together with increased MPTP toxicity in dopaminergic neurons [43,44].”
ResultMinocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146 · cited 1×
“After that, the same group conducted an OLS in a small cohort of 22 participants with SCZ resistant to treatment (4 weeks of minocycline), corroborating these positive outcomes [104].”
MethodZabad, R. K., Metz, L. M., Todoruk, T. R., Zhang, Y., Mitchell, J. R., Yeung, M., Patry, D. G., Bell, R. B., & Yong, V. W. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506070319 · Cited by 120
Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice
Stack, E. C., Smith, K. M., Ryu, H., Cormier, K., Chen, M., Hagerty, S. W., Del Signore, S. J., Cudkowicz, M. E., Friedlander, R. M., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.11.002 · Cited by 114 · cited 1×
“On the one hand, some studies have reported significant biochemical and behavioral improvements [50-57].”
BackgroundMajidi, J., Kosari-Nasab, M., & Salari, A.-A. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.10.009 · Cited by 109 · cited 1×
“Since the first preclinical study in 2007, several studies have shown that minocycline improves anxiety in different behavioral tests, especially forced swimming, tail suspension and open field tests [131-139], together with reduction of inflammation and/or inflammatory mediators [132,135,137,139-142] and recovery of…”
BackgroundAnti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy
Garwood, C. J., Cooper, J. D., Hanger, D. P., & Noble, W. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00136 · Cited by 106 · cited 1×
“In addition, it led to relief of neuroinflammation [14-18], neuronal death [19], and pro-apoptotic factors [20] and an attenuation in the loss of forebrain cholinergic neurons [21].”
BackgroundKhodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.051 · Cited by 104 · cited 1×
“Three more trials reinforced previous positive results, evidencing a general clinical improvement, not only in negative symptoms [111,112], but also in working memory, anxiety and depression symptoms [113] after 8 weeks of treatment (200 mg/day).”
ResultLong-lasting effects of minocycline on behavior in young but not adult Fragile X mice.
Dansie, L. E., Phommahaxay, K., Okusanya, A. G., Uwadia, J., Huang, M., Rotschafer, S. E., Razak, K. A., Ethell, D. W., & Ethell, I. M. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.058 · Cited by 95 · cited 1×
“The remaining studies, performed in the Fmr1-KO mice model, reported behavioral improvements in locomotor activity, anxiety and exploratory memory [120-123], increment of dendritic spines maturation [120], reduction of seizure severity in young mice [122], and recovery in the function of the N-methyl-D-aspartate (NMDA…”
BackgroundThe Therapeutic Role of Minocycline in Parkinson’s Disease
Cankaya, S., Cankaya, B., Kilic, U., Kilic, E., & Yulug, B. (2019) · Drugs in Context · doi:10.7573/dic.212553 · Cited by 93
Pusic, K. M., Pusic, A. D., Kemme, J., & Kraig, R. P. (2014) · Glia · doi:10.1002/glia.22672 · Cited by 85 · cited 1×
“It is known that inflammation mediated by microglial activation is closely related to the onset of depression [130].”
BackgroundCronin, A., & Grealy, M. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.10.018 · Cited by 68 · cited 1×
“Additionally, minocycline produced significant neuroprotection in transgenic models of PD in rodents [33,38], Drosophila melanogaster [39-41] and zebrafish [42].”
BackgroundQuintero, E. M., Willis, L., Singleton, R., Harris, N., Huang, P., Bhat, N., & Granholm, A.-C. (2006) · Brain Research · doi:10.1016/j.brainres.2006.03.104 · Cited by 58 · cited 1×
“In different rodent models, minocycline proved to be effective as a neuroprotective agent against diverse compounds with parkinsonian-like effects, such as the neurotoxins 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [28-31], 6-hydroxydopamine (6-OHDA) [32], rotenone [33-35] or paraquat [31], and other compound…”
BackgroundA pilot open-label trial of minocycline in patients with autism and regressive features
Pardo, C. A., Buckley, A., Thurm, A., Lee, L.-C., Azhagiri, A., Neville, D. M., & Swedo, S. E. (2013) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-5-9 · Cited by 58
Peng, J., Xie, L., Stevenson, F. F., Melov, S., Di Monte, D. A., & Andersen, J. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3447-06.2006 · Cited by 53 · cited 1×
“Additionally, minocycline produced significant neuroprotection in transgenic models of PD in rodents [33,38], Drosophila melanogaster [39-41] and zebrafish [42].”
BackgroundRice, A. S. C., Morland, R., Huang, W., Currie, G. L., Sena, E. S., & Macleod, M. R. (2013) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2013.02.002 · Cited by 42 · cited 1×
“This bias becomes more evident in preclinical studies than in clinical trials, and presents a clear obstacle for reviews and meta-analyses to reach unbiased conclusions [165,166].”
BackgroundChaves, C., Marque, C. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., Ferrari, T. B., Santos, A. C., Araújo, D., Machado-de-Sousa, J. P., Bressan, R. A., Elkis, H., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.031 · Cited by 41
Sun, C., Wang, Y., Mo, M., Song, C., Wang, X., Chen, S., & Liu, Y. (2019) · BioMed Research International · doi:10.1155/2019/6843265 · Cited by 37
Kumar, V., Singh, B. K., Chauhan, A. K., Singh, D., Patel, D. K., & Singh, C. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9137-y · Cited by 37
Cited by
Alzheimer’s Disease: An Update and Insights Into Pathophysiology
Abubakar, M. B., Sanusi, K. O., Ugusman, A., Mohamed, W., Kamal, H., Ibrahim, N. H., Khoo, C. S., & Kumar, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.742408 · Cited by 279
Antibiotics and mental health: the good, the bad and the ugly
Dinan, K., & Dinan, T. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13543 · Cited by 69
Between Dysbiosis, Maternal Immune Activation and Autism: Is There a Common Pathway?
Suprunowicz, M., Tomaszek, N., Urbaniak, A., Zackiewicz, K., Modzelewski, S., & Waszkiewicz, N. (2024) · Nutrients · doi:10.3390/nu16040549 · Cited by 44
“Minocycline is a broad-spectrum tetracycline antibiotic, which, primarily, is used to treat bacterial infections but also has a neuroprotective, anti-inflammatory, and antioxidant effect [290,291].”
Background
Metadata
- Authors
- Romero‐Miguel, D., Lamanna‐Rama, N., Casquero‐Veiga, M., Gómez‐Rangel, V., Desco, M., & Soto‐Montenegro, M. L.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2020-12-24
- Volume
- 28
- Issue
- 3
- Pages
- 1056-1081
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W3105773270
- Cited by
- 93
- References
- 42
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.